{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:33:39Z","timestamp":1790066019650,"version":"4.0.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006398","name":"Roswell Park Alliance Foundation, Roswell Park Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016506"],"award-info":[{"award-number":["P30CA016506"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.blre.2020.100696","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T11:46:58Z","timestamp":1588852018000},"page":"100696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias"],"prefix":"10.1016","volume":"45","author":[{"given":"Claire","family":"Fritz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Portwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Przespolewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7035","key":"10.1016\/j.blre.2020.100696_bb0005","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature."},{"issue":"8","key":"10.1016\/j.blre.2020.100696_bb0010","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Am\u00e9","year":"2004","journal-title":"BioEssays."},{"issue":"25","key":"10.1016\/j.blre.2020.100696_bb0015","doi-asserted-by":"crossref","first-page":"17860","DOI":"10.1074\/jbc.274.25.17860","article-title":"PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase","volume":"274","author":"Ame","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.blre.2020.100696_bb0020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-ribose): novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.blre.2020.100696_bb0025","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1074\/jbc.M110.202507","article-title":"Crystal structures of poly(ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: structural and functional insights into DNA-dependent PARP-1 activity","volume":"286","author":"Langelier","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.blre.2020.100696_bb0030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/jpet.114.222448","article-title":"Trapping poly(ADP-ribose) polymerase","volume":"353","author":"Shen","year":"2015","journal-title":"J. Pharm. Exp. Ther."},{"issue":"21","key":"10.1016\/j.blre.2020.100696_bb0035","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Huang S-yN, das BB, Renaud a, Zhang Y, Doroshow JH, et al. trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.blre.2020.100696_bb0040","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and Olaparib in metastatic prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.blre.2020.100696_bb0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ctrv.2018.05.014","article-title":"Emerging therapeutic modalities of PARP inhibitors in breast cancer","volume":"68","author":"Wang","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.blre.2020.100696_bb0050","doi-asserted-by":"crossref","first-page":"933","DOI":"10.6004\/jnccn.2018.7020","article-title":"DNA repair gene alterations and PARP inhibitor response in patients with metastatic castration-resistant prostate Cancer","volume":"16","author":"Lu","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.blre.2020.100696_bb0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.critrevonc.2018.10.012","article-title":"Targeting homologous repair deficiency in breast and ovarian cancers: biological pathways, preclinical and clinical data","volume":"133","author":"Chartron","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"19","key":"10.1016\/j.blre.2020.100696_bb0060","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: Olaparib monotherapy in patients with deleterious Germline BRCA-mutated advanced ovarian Cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.blre.2020.100696_bb0065","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast Cancer and a Germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.blre.2020.100696_bb0070","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.blre.2020.100696_bb0075","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10106","key":"10.1016\/j.blre.2020.100696_bb0080","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet."},{"issue":"22","key":"10.1016\/j.blre.2020.100696_bb0085","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.blre.2020.100696_bb0090","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.mam.2013.01.005","article-title":"PARP-1 and gene regulation: progress and puzzles","volume":"34","author":"Kraus","year":"2013","journal-title":"Mol. Asp. Med."},{"issue":"6","key":"10.1016\/j.blre.2020.100696_bb0095","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.mam.2012.12.005","article-title":"Reprogramming cellular events by poly(ADP-ribose)-binding proteins","volume":"34","author":"Krietsch","year":"2013","journal-title":"Mol. Asp. Med."},{"issue":"10","key":"10.1016\/j.blre.2020.100696_bb0100","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.exphem.2016.07.007","article-title":"PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment","volume":"44","author":"Zhao","year":"2016","journal-title":"Exp. Hematol."},{"issue":"6","key":"10.1016\/j.blre.2020.100696_bb0105","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00412-014-0482-9","article-title":"DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance","volume":"123","author":"Esposito","year":"2014","journal-title":"Chromosoma."},{"issue":"7520","key":"10.1016\/j.blre.2020.100696_bb0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature13483","article-title":"DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier","volume":"514","author":"Santos","year":"2014","journal-title":"Nature."},{"issue":"10","key":"10.1016\/j.blre.2020.100696_bb0115","first-page":"2791","article-title":"Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70\/86 heterodimer","volume":"62","author":"Gaymes","year":"2002","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.blre.2020.100696_bb0120","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"20","key":"10.1016\/j.blre.2020.100696_bb0125","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1021\/jm8001263","article-title":"4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1","volume":"51","author":"Menear","year":"2008","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.blre.2020.100696_bb0130","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/sj.leu.2404376","article-title":"Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: focus on DNA repair genes","volume":"20","author":"Casorelli","year":"2006","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2020.100696_bb0135","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1021\/jm5018237","article-title":"Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of Tumors with defective homologous recombination","volume":"58","author":"Jones","year":"2015","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.blre.2020.100696_bb0140","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ccell.2016.09.002","article-title":"Enhancing the cytotoxic effects of PARP inhibitors with DNA Demethylating agents - a potential therapy for Cancer","volume":"30","author":"Muvarak","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.blre.2020.100696_bb0145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1021\/acs.jmedchem.5b01498","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.blre.2020.100696_bb0150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3892\/ijo.2014.2726","article-title":"PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA\/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226\/R","volume":"46","author":"Xiong","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"10","key":"10.1016\/j.blre.2020.100696_bb0155","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.dnarep.2011.07.006","article-title":"The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest","volume":"10","author":"Madison","year":"2011","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.blre.2020.100696_bb0160","author":"Research"},{"issue":"20","key":"10.1016\/j.blre.2020.100696_bb0165","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1016\/j.bmcl.2015.08.060","article-title":"Identification of novel PARP-1 inhibitors: drug design, synthesis and biological evaluation","volume":"25","author":"Xie","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.blre.2020.100696_bb0170","author":"Research"},{"issue":"1","key":"10.1016\/j.blre.2020.100696_bb0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/asheducation-2014.1.14","article-title":"Treating acute myeloid leukemia in older adults","volume":"2014","author":"Wang","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.blre.2020.100696_bb0180","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.bbadis.2014.12.001","article-title":"BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: role as biomarkers of response to the PARP inhibitor olaparib","volume":"1852","author":"Faraoni","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.blre.2020.100696_bb0185","first-page":"5487","article-title":"Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells","volume":"34","author":"Yamauchi","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.blre.2020.100696_bb0190","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood.V128.22.1645.1645","article-title":"Combining IMGN779, a novel anti-CD33 antibody-drug conjugate (ADC), with the PARP inhibitor, Olaparib, results in enhanced anti-tumor activity in preclinical acute myeloid Leukemia (AML) models","volume":"128","author":"Portwood","year":"2016","journal-title":"Blood."},{"issue":"29","key":"10.1016\/j.blre.2020.100696_bb0195","doi-asserted-by":"crossref","first-page":"27490","DOI":"10.18632\/oncotarget.4748","article-title":"Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.blre.2020.100696_bb0200","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.leukres.2016.03.007","article-title":"Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin","volume":"45","author":"Robert","year":"2016","journal-title":"Leuk. Res."},{"issue":"14","key":"10.1016\/j.blre.2020.100696_bb0205","doi-asserted-by":"crossref","first-page":"9108","DOI":"10.1093\/nar\/gku638","article-title":"The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2\u2032-deoxycytidine lesions","volume":"42","author":"Orta","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.blre.2020.100696_bb0210","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3324\/haematol.2008.001933","article-title":"Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes","volume":"94","author":"Gaymes","year":"2009","journal-title":"Haematologica."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2020.100696_bb0215","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1182\/blood-2018-99-117214","article-title":"Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models","volume":"132","author":"Fritz","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2020.100696_bb0220","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ceb.2010.08.001","article-title":"Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation","volume":"22","author":"Yang","year":"2010","journal-title":"Curr. Opin. Cell Biol."},{"issue":"30","key":"10.1016\/j.blre.2020.100696_bb0225","doi-asserted-by":"crossref","first-page":"20543","DOI":"10.1074\/jbc.M114.549220","article-title":"Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression","volume":"289","author":"Meng","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.blre.2020.100696_bb0230","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1158\/1535-7163.MCT-16-0660","article-title":"A small-molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing dna damage and apoptosis in acute leukemia","volume":"16","author":"Garcia","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"26","key":"10.1016\/j.blre.2020.100696_bb0235","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1182\/blood-2017-05-784942","article-title":"Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms","volume":"130","author":"Nieborowska-Skorska","year":"2017","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2020.100696_bb0240","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-13-1333","article-title":"Molecular pathways: Isocitrate dehydrogenase mutations in Cancer","volume":"22","author":"Clark","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.blre.2020.100696_bb0245","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1101\/gad.217406.113","article-title":"What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer","volume":"27","author":"Losman","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.blre.2020.100696_bb0250","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.blre.2020.100696_bb0255","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1078-0432.CCR-17-2796","article-title":"IDH1\/2 mutations sensitize acute myeloid Leukemia to PARP inhibition and this is reversed by IDH1\/2-mutant inhibitors","volume":"24","author":"Molenaar","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.blre.2020.100696_bb0260","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2018-02-834895","article-title":"Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors","volume":"132","author":"Maifrede","year":"2018","journal-title":"Blood."},{"issue":"13","key":"10.1016\/j.blre.2020.100696_bb0265","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.4161\/cbt.8.13.8924","article-title":"MLL fusions: pathways to leukemia","volume":"8","author":"Liu","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.blre.2020.100696_bb0270","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1182\/bloodadvances.2017006247","article-title":"MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs","volume":"1","author":"Maifrede","year":"2017","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.blre.2020.100696_bb0275","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/nm.3993","article-title":"Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors","volume":"21","author":"Esposito","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.blre.2020.100696_bb0280","first-page":"1388","article-title":"MiR-181a Down-regulates PARP1 by enhancing its acetylation in MLL -rearranged AML","volume":"130","author":"Zhou","year":"2017","journal-title":"Blood."},{"issue":"5340","key":"10.1016\/j.blre.2020.100696_bb0285","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.278.5340.1059","article-title":"Oncogenic transcription factors in the human acute leukemias","volume":"278","author":"Look","year":"1997","journal-title":"Science."},{"issue":"11","key":"10.1016\/j.blre.2020.100696_bb0290","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1172\/JCI17595","article-title":"Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair","volume":"112","author":"Alcalay","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.blre.2020.100696_bb0295","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/leu.2015.133","article-title":"The leukemia-associated RUNX1\/ETO oncoprotein confers a mutator phenotype","volume":"30","author":"Forster","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100696_bb0300","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V128.22.4063.4063","article-title":"The PARP inhibitor Olaparib antagonizes leukemic growth induced by TET1 overexpression in AML1-ETO positive acute myeloid Leukemia","volume":"128","author":"Bamezai","year":"2016","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2020.100696_bb0305","first-page":"379","article-title":"Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002","volume":"19","author":"Yamamoto","year":"2008","journal-title":"Cancer Causes Control"},{"issue":"4","key":"10.1016\/j.blre.2020.100696_bb0310","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/1535-7163.MCT-14-0276","article-title":"The combination of the PARP inhibitor Rucaparib and 5FU is an effective strategy for treating acute Leukemias","volume":"14","author":"Falzacappa","year":"2015","journal-title":"Mol Can Ther"},{"issue":"7","key":"10.1016\/j.blre.2020.100696_bb0315","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1080\/10428194.2017.1397662","article-title":"Drugging DNA repair to target T-ALL cells","volume":"59","author":"Dasgupta","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"6144","key":"10.1016\/j.blre.2020.100696_bb0320","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.1236188","article-title":"Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress","volume":"341","author":"Bassi","year":"2013","journal-title":"Science."},{"issue":"6\u20137","key":"10.1016\/j.blre.2020.100696_bb0325","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.blre.2020.100696_bb0330","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cell.2006.11.042","article-title":"Essential role for nuclear PTEN in maintaining chromosomal integrity","volume":"128","author":"Shen","year":"2007","journal-title":"Cell."},{"key":"10.1016\/j.blre.2020.100696_bb0335","first-page":"3347","article-title":"DNA Demethylating agents generate a Brcaness effect in multiple sporadic tumor types: prediction for sensitivity to PARP inhibitors in AML","volume":"130","author":"Kogan","year":"2017","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.blre.2020.100696_bb0340","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.4161\/15384101.2014.965013","article-title":"Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation","volume":"13","author":"Podszywalow-Bartnicka","year":"2014","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.blre.2020.100696_bb0345","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1172\/JCI90825","article-title":"Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells","volume":"127","author":"Nieborowska-Skorska","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.blre.2020.100696_bb0350","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/10428194.2018.1471602","article-title":"PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions","volume":"60","author":"Podszywalow-Bartnicka","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2020.100696_bb0355","first-page":"33","article-title":"Results of a phase 1 study of BMN 673, a potent and specific PARP-1\/2 inhibitor, in patients with advanced Hematological malignancies","volume":"99","author":"Mufti","year":"2014","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.blre.2020.100696_bb0360","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1078-0432.CCR-16-0984","article-title":"A phase 1 study of the PARP inhibitor Veliparib in combination with Temozolomide in acute myeloid Leukemia","volume":"23","author":"Gojo","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.blre.2020.100696_bb0365","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/1078-0432.CCR-16-1274","article-title":"A phase I study of Topotecan, carboplatin and the PARP inhibitor Veliparib in acute Leukemias, aggressive Myeloproliferative neoplasms, and chronic Myelomonocytic Leukemia","volume":"23","author":"Pratz","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.blre.2020.100696_bb0370","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/1541-7786.MCR-06-0111","article-title":"Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?","volume":"4","author":"Gaymes","year":"2006","journal-title":"Mol. Cancer Res."},{"issue":"2","key":"10.1016\/j.blre.2020.100696_bb0375","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/fon.11.2","article-title":"Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer","volume":"7","author":"Thurn","year":"2011","journal-title":"Future Oncol."},{"issue":"11","key":"10.1016\/j.blre.2020.100696_bb0380","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.celrep.2018.05.034","article-title":"Simultaneous targeting of PARP1 and RAD52 triggers dual synthetic lethality in BRCA-deficient tumor cells","volume":"23","author":"Sullivan-Reed","year":"2018","journal-title":"Cell Rep."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:28:01Z","timestamp":1759436881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":76,"alternative-id":["S0268960X20300461"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100696","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100696"}}